Iran Faces Deepening Medicine Shortage as US Sanctions Block Pharmaceutical Supply Chains

The Quick Take

• US sanctions against Iran have caused significant pharmaceutical shortages, making medicine procurement increasingly difficult for Iranian hospitals and patients.
• Washington's isolation campaign has effectively blocked international pharmaceutical companies from supplying the Iranian market due to sanctions compliance risk.
• Both imported medicines and domestically produced pharmaceuticals dependent on foreign raw materials are affected, deepening the healthcare supply crisis.

US economic sanctions against Iran have extended their impact beyond the energy and financial sectors into healthcare, creating measurable pharmaceutical supply shortages that the Financial Times is highlighting as a systemic challenge. While US sanctions include formal humanitarian exemptions for medicines and food, the secondary sanctions risk — where non-US companies fear penalties for any Iran-linked transactions — has led most major multinational pharmaceutical manufacturers and distributors to exit the Iranian market entirely, regardless of the technical legal carve-outs.

The pharmaceutical shortage has investment and policy implications across several dimensions. For global pharma companies like Roche, Novartis, and Pfizer, the Iran market has been effectively zero-revenue for years due to sanctions compliance requirements, but the FT's reporting signals that the gap between formal exemptions and real market access is widening. Iran's domestic pharmaceutical manufacturers are under strain from restricted access to active pharmaceutical ingredients from European and Asian suppliers, creating input cost pressures that parallel the energy supply shock experienced after 2018 sanctions reimposition.

Investors tracking Iran sanctions policy should watch for signals from the Trump-Iran diplomatic standoff's outcome, as any sanctions relaxation — however unlikely under current conditions — would represent a material upside catalyst for emerging market pharmaceutical companies in the region. The macro variable is the US maximum-pressure campaign's durability: if Iran's civilian healthcare deterioration draws significant international criticism, European governments could pursue autonomous humanitarian supply channels that partially bypass the sanctions framework, creating a policy divergence between Washington and Brussels.

Synthesized from 1 source.